Key statistics
On Friday, Sarepta Therapeutics Inc (AB3A:DUS) closed at 15.50, 7.94% above its 52-week low of 14.36, set on Jul 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.01 |
---|---|
High | 16.03 |
Low | 15.50 |
Bid | 15.51 |
Offer | 15.60 |
Previous close | 16.50 |
Average volume | 239.00 |
---|---|
Shares outstanding | 98.28m |
Free float | 91.35m |
P/E (TTM) | -- |
Market cap | 1.87bn USD |
EPS (TTM) | -2.87 USD |
Data delayed at least 15 minutes, as of Jul 11 2025 18:31 BST.
More ▼
Press releases
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne
- U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4
- Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy
- Sarepta Therapeutics Shares New Protein Expression and Safety Results from ENDEAVOR in Participants 2 Years Old at Time of Treatment
- Sarepta Therapeutics Presents Data at the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2
- Sarepta Therapeutics Announces Approval in Japan of ELEVIDYS, a Gene Therapy to Treat Duchenne Muscular Dystrophy
- Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
- Sarepta Therapeutics Announces First Quarter 2025 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
More ▼